USPTO 2015–2025 USPTO PatentsView US Corporation

Tcr2 Therapeutics Inc.

USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Tcr2 ranks #27,580 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 4 technology areas.

#27,580
of 49,997 US assignees by volume
48th percentile
by Innovation Score (34.4/100)
24.4
avg claims per patent
+50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R27580 · US Corporation #27,580 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 10 grants
  • MID-PACK #27,580/49,997
  • PHOTO-FINISH Taro Pharmaceutical…
  • CPC-NARROW A61P · 4 areas
  • INNOV-THIN 34.4/100
  • CLAIMS-DENSE 24.4 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +50% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Taro Pharmaceutical Industries Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Tcr2

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Tcr2's Innovation Score is 34.4/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Tcr2's grants concentrate

Tcr2 Therapeutics Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2023. By volume, Tcr2 sits between Taro Pharmaceutical Industries Ltd. and Technoguard Inc..

Tcr2's three-year grant acceleration

Tcr2 Therapeutics Inc. shows 4 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Tcr2's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Tcr2 holds 10 patents at rank #27,564, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Tcr2

By rank, the assignees closest to #27,564 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Tcr2's primary technology class.

Tcr2's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 48th percentile higher than 48% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20192021202220232024 1
USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Tcr2 Therapeutics Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 4 40.0%
2021 2 20.0%
2022 2 20.0%
2023 1 10.0%
2024 1 10.0%

Where it ranks

Overall rank by patents

#27,580

of 49,997 tracked assignees

Innovation Score

34.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Tcr2 Therapeutics Inc.'s patent record in context - here's where to go next.

  • Tcr2 Therapeutics Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #27,580 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Tcr2 Therapeutics Inc. against Taro Pharmaceutical Industries Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 34.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.